Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma.

Carlo LombardiAlvise BertiMarcello CottiniElena RocaLaura Ventura

Published in: ERJ open research (2023)

The 6MWT could complement severe asthma assessment and be relevant in evaluating the objective response to treatment, including biological therapies like mepolizumab.

Keyphrases

chronic obstructive pulmonary disease
early onset
stem cells
allergic rhinitis
combination therapy
mesenchymal stem cells
smoking cessation